SCHEMBL4777553

SCHEMBL4777553

Cc1ccc(N(Cc2cccc(Cl)c2Cl)S(C)(=O)=O)cc1

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
RECQL P46063 1/20 0.48
LMNA P02545 2/20 0.46
POLB P06746 1/20 0.46
GAA P10253 1/20 0.43
NPSR1 Q6W5P4 3/20 0.41
MAPT P10636 2/20 0.41
HTT P42858 1/20 0.41
HCRTR2 O43614 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
OXTR P30559 1/20 0.40
REN P00797 1/20 0.39
PER2 O15055 1/20 0.39
CRY1 Q16526 1/20 0.39
CRY2 Q49AN0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4771201 0.90 LMNA (0.50) ALDH1A1KDM4ESMN1; SMN2RECQLLMNA
SCHEMBL4772377 0.86 PNMT (0.47) ALDH1A1KDM4ESMN1; SMN2RECQLLMNA
SCHEMBL4773540 0.86 GAA (0.43) ALDH1A1KDM4ESMN1; SMN2RECQLLMNA
SCHEMBL4777644 0.85 GAA (0.45) ALDH1A1SMN1; SMN2RECQLLMNAPOLB
SCHEMBL4777413 0.85 KDM4E (0.52) ALDH1A1KDM4ELMNAPOLBGAA
SCHEMBL4773541 0.84 GAA (0.42) ALDH1A1KDM4ERECQLLMNAGAA
SCHEMBL4773076 0.84 PER2 (0.43) ALDH1A1KDM4ESMN1; SMN2RECQLLMNA
SCHEMBL4767920 0.84 NR1H4 (0.50) ALDH1A1SMN1; SMN2LMNAGAANPSR1
SCHEMBL4775349 0.83 LMNA (0.41) ALDH1A1KDM4ESMN1; SMN2RECQLLMNA
SCHEMBL4792816 0.83 ALDH1A1 (0.41) ALDH1A1KDM4ESMN1; SMN2RECQLLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 ALDH1A1 2159/4885KDM4E 3267/4885SMN1; SMN2 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.